Luna Acharya, MD MA

Hematologist-Oncologist @MercyOne_Iowa, HO fellow @UIowa, IM @MountSinaiNYC, Psych Grad

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

Pancreatic cancer will look very different in 5 years

✅ KRAS is no longer "undruggable"
✅ Neoantigen vaccines may stop recurrence
✅ AI can identify 'occult' tumors from routine scans

We tackle these stories in our new episode!

#onlyoncologistsinthebuilding

[Paolo Tarantino @PTarantinoMD]

This study deserved an oral presentation, btw

[Dr. Cathy Eng @CathyEngMD]

2025 Fast Facts:
🔷154,270 will be diagnosed
🔷 19,330 patients < 50 y/o
We created a video using @Vidyard discussing the benefit of #colorectalcancer #cancerprevention. https://t.co/X9XQHQRrpY
#ColorectalCancerAwarenessMonth @FightCRC @OncoAlert @VUMC_Cancer @VUMCDiscoveries

[Toni Choueiri, MD @DrChoueiri]

Detecting lung cancer 5 years before it happens, in @CellCellPress courtesy of the @CharlesSwanton group.

Astonishing translational work !

https://t.co/EvUmIGVLgs

[CBS Evening News with Tony Dokoupil @CBSEveningNews]

An experimental drug called daraxonrasib nearly doubled overall survival rates for patients with advanced pancreatic cancer, according to the results of a newly published study. @DrLaPook has more on the findings. https://t.co/jl4OMupucA

[Thor Halfdanarson @OncoThor]

My other hat in clinic than NET/GI is unknown primary cancer (CUP) and rare cancers that do not fit neatly in other tumor groups. One such cancer is extramammary Paget's disease (EMPD). It is almost as if I like to work in the data-free/data-limited zone... 😉

Metastatic EMPD is a rare malignancy, in fact, extremely rare. Therefore, very little is known about the management.

Thanks to @SuleimanRiham, @hfuentesbayne, @StephanThomeMD and others, we now have a little more information.

A few highlights:

-- Median overall survival (OS) 20.0 months
-- IHC showed universal CK7 and GATA3 positivity, with 80% androgen receptor (AR) expression.
-- HER2 was positive (3+) or amplified in approximately one-third of cases.
-- NGS revealed frequent mutations in TP53 (68.8%), ERBB2 (50%), and CDKN2A/B (50%). A “triple-hit” deletion at the 9p21 locus (CDKN2A/B/MTAP) was identified in 25% of cases.
-- Genomic profiling showed strong similarity to HER2+ breast and urothelial carcinomas.
-- HER2-directed therapy was associated with longer overall survival (median OS 73.0 months [95% CI, 0–177.9] vs. 19.0 months (NS)

https://t.co/ZTaX8b7qq8

[NEJM @NEJM]

In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy. Full phase 3 HERIZON-GEA-01 trial results and Research Summary: https://t.co/ShqcYpSvVb

[Oncology Brothers @OncBrothers]

Day 3 #ASCO26 5 plenary highlights:

1. #PROTEUS: PeriOp/PostOp Apa in Prostate Ca

2. #SARC041: Adj Abema in dediff liposarcoma

3. #LIBRETTO432 : Adj Selpercatinib in NSCLC

4. #HARMONi6: 1L Ivonescimab in Sq mNSCLC

5. #RASolute302: 2L Daraxonrasib in Panc Ca

@ASCO

1/6

[Dr. Cathy Eng @CathyEngMD]

Another possible option for HER-2 mCRC?
#ASCO26 Phase III trasutuzumab rezetecan vs. SOC for #HER2 mCRC @ASCO #cancer #cancerresearch @OncoAlert #colorectalcancer #cancer
👉Improved PFS
👉Improved ORR
👉 Immature OS

[John P. Leonard, MD @JohnPLeonardMD]

Paul Oberstein, co-author and investigator on the #ASCO26 daraxonrasib plenary presentation and @NEJM paper in pancreatic cancer describes the key findings of the study (which received a standing ovation!) @nyulangone @nyugrossman @Perlmutter_CC @Aiims1742

[Dr Amol Akhade @SuyogCancer]

Another money 💰 slide.
Summary of all adjuvant targeted therapy trials in Resectable NSCLC. Taken from the talk by @ROsarogiagbon @ASCO #asco26

[Paolo Tarantino @PTarantinoMD]

Only few days to #ASCO26. For breast oncologists, this edition will deliver a new promising biomarker to spare unnecessary chemo, informative updates from practice-changing trials across subtypes, and major innovations coming from China. See you in Chicago next week! #bcsm

[Ronan Hsieh, MD, MS @ronanhsieh]

#ASCO26 is coming soon. Below are the seven GI cancer abstracts that could change the current standard of care if results are positive. Stay tuned.

@ASCO @jgong15 @RevMedicines @SWOG @VanMorrisMD @skopetz @ArndtVogel @GIcancerDoc @ProvSwedish #Daraxonrasib #Pemigatinib #colorectalcancer #HCC #BTC #cholangiocarcinoma #pancreaticcancer #PDAC @curecc

[Xiuning Le MD PhD @LeXiuning]

At #ASCO26, the @UTMDAnderson Thoracic Medical Oncology Department will deliver an incredible 9 oral presentations💐💐💐 highlighting advances across ##EGFR, #HER2, #KRAS, #KEAP1/STK11, #SCLC, IO, #peri-operative, all lung cancer subgroups. For perspective, thoracic medical oncologists from China have 16 oral presentations.
👩‍⚕️🧑‍⚕️ 👩‍🔬🧑‍🔬Our entire MDA Thoracic team @FSkoulidis @NIVokes @LaurenByersMD @lungoncdoc Drs. Heymach, Cascone, Zhang, @mvnegrao @YYElamin @AnneTsao2 are deeply proud and excited 😀to help shape the future of lung cancer research and patient care alongside outstanding collaborators and industry partners.

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

🫁 My pick of 10 lung cancer trials that will define practice at #ASCO2026 @ASCO

From sunvozertinib in exon20ins to 7-year CROWN data to TRITON in STK11/KEAP1/KRAS; the data is coming.

Which one are you watching?

@OncoAlert @LungCancerRx @oncodaily @EGFRResisters @KRASKickers

[Stephen V Liu, MD @StephenVLiu]

An honor to be part of this consensus statement from the @IASLC Advanced Radiation Technology Subcommittee @JTOonline on radiotherapy to the primary tumor in stage IV NSCLC, led by Drs. Ryan McMahon and @_ShankarSiva. Is it time to rethink management of metastatic lung cancer?

[Thor Halfdanarson @OncoThor]

How does somatostatin PET perform in detecting nodal metastases in patients with pancreatic NETs evaluated for resection? Not so great...

130 patients w/ pNETs who all had SSTR PET followed by resection. 42% had path proven LN mets but only 24% were seen preop on PET (sensitivity 46%). Specificity much better, 92% with PPV of 81% and NPV of only 29%.
As expected, larger nodes and a higher Krenning score were more likely to be found on SSTR PET.
Be careful with multifocal pNETs such as in MEN1 as multifocality can resemble nodal mets.

@TELL_Starlinger @ThielsCA @PackardAnnie @MayoRadiology @MayoClinicSurg @MayoCancerCare @MayoHemeOnc

https://t.co/pJg3IMNAmP

[Toni Choueiri, MD @DrChoueiri]

ASCO GU 2026 – Top 15 Trials with Potential Practice Impact @ASCO #GU26

[Dr Amol Akhade @SuyogCancer]

Whats new and exciting data to look forward in ASCO GU 2026 🙂👇 @ASCO #ASCOGU26 @brunolarvol @MedwatchKate

[Luna Acharya, MD MA @LAcharyaMD]

@GIMedOnc @AnthemBCBS @CarelonRx I had a similar situation. Patients pay premiums for years only to be denied in time of need. This is sad!